节点文献

多肽GRGDS修饰的紫杉醇长循环靶向脂质体的体外评价

In vitro evaluation of GRGDS peptide modified liposomes containing paclitaxel

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 赵慧王坚成罗春蕾孙启时张强

【Author】 ZHAO Hui1,2,WANG Jian-cheng1,LUO Chun-lei1,SUN Qi-shi2,ZHANG Qiang1,3(1 Department of Pharmaceutics,School of Pharmaceutical Sciences,Peking University,Beijing 100191,China;2 School of Traditional Chinese Medicine,Shenyang Pharmaceutical University,Shenyang 110016,China;3 State Key Laboratory of Natural and Biomimetic Drugs,Peking University,Beijing 100191,China)

【机构】 北京大学药学院药剂学系沈阳药科大学中药学院北京大学天然药物与仿生药物国家重点实验室

【摘要】 目的:本研究以甘氨酸-精氨酸-甘氨酸-天冬氨酸-丝氨酸(glycine-arginine-glycine-aspartic acid-serine,GRGDS)五肽修饰的脂质体作为抗癌药物-紫杉醇的载体,对其体外理化性质和细胞毒作用进行评价。方法:采用化学偶联合成DSPE-PEG-GRGDS,以此作为导向性材料,采用薄膜分散法制备载紫杉醇的PEG修饰长循环脂质体(GRGDS-SSL-PTX),并对脂质体的包封率、粒径和体外释放率等性质进行了考察,同时采用人卵巢癌SKOV-3细胞和人乳腺癌MCF-7细胞进行了体外细胞生长抑制的评价。结果:与普通紫杉醇长循环脂质体(SSL-PTX)相比,本研究制备的紫杉醇主动靶向脂质体(GRGDS-SSL-PTX)的粒径、包封率、载药量、体外释放及稳定性等理化性质无显著差异,包封率约为95%,平均粒径为(115.5±2.2)和(117.5±1.3)nm。冰冻蚀刻透射电镜观察结果表明,脂质体外观基本圆整且均匀分散。体外释放结果表明,12 h内分别有67.9%和72.3%的PTX从SSL-PTX和GRGDS-SSL-PTX中释放。体外细胞毒实验结果表明,GRGDS-SSL-PTX对人卵巢癌SKOV-3细胞和人乳腺癌MCF-7细胞的生长抑制作用均有增强,分别为SSL-PTX的1.42倍和2.12倍。结论:GRGDS五肽修饰的紫杉醇靶向脂质体成功制备,将有利于体内肿瘤的靶向治疗效果。

【Abstract】 Objective:To investigate the glycine-argine-glycine-aspartic acid-serine(GRGDS) modified long circulating liposomes as the carriers of anticancer drug of paclitaxel.Methods:The DSPE-PEG-GRGDS synthesized by DSPE-PEG-NHS and GRGDS was used as liposome materials to obtain the paclitaxel loaded liposomes(GRGDS-SSL-PTX).The encapsulation efficiency,drug loading,particle size and in vitro release and cytotoxicity were performed.Results:The encapsulation efficiencies of the liposomes were above 95% and the modification of GRGDS showed no effect on the physicochemical characters,such as particle size,encapsulation efficiency and in vitro release.The average size of SSL-PTX and GRGDS-SSL-PTX were(115.5±2.2)nm and(117.5±1.3)nm respectively.The release of paclitaxel between the SSL-PTX and GRGDS-SSL-PTX within 12h has demonstrated to be 67.9% and 72.3%.In vitro cytotoxicities were increased by 1.42 fold in SKOV3 and 2.12 fold in MCF-7.Conclusion:GRGDS-SSL-PTX might be a potential formulation for targeting cancer therapy in patients.

【关键词】 整合素脂质体紫杉醇靶向
【Key words】 integrinliposomepaclitaxeltarget
【基金】 国家自然科学基金(30572261);国家重大基础研究计划973项目(2007CB935801)
  • 【文献出处】 中国新药杂志 ,Chinese Journal of New Drugs , 编辑部邮箱 ,2008年23期
  • 【分类号】R943.42
  • 【被引频次】21
  • 【下载频次】922
节点文献中: 

本文链接的文献网络图示:

本文的引文网络